Andreas Scheel
Direktor/Vorstandsmitglied bei Pancella Therapeutics, Inc.
Profil
Andreas Scheel has held positions as a Director at panCELLa, Inc. and as a Member-Supervisory Board at Pancella Therapeutics, Inc.
Aktive Positionen von Andreas Scheel
| Unternehmen | Position | Beginn |
|---|---|---|
Pancella Therapeutics, Inc.
 Pancella Therapeutics, Inc. BiotechnologyHealth Technology Pancella Therapeutics, Inc. develops novel therapies for geno dermatoses. The company is headquartered in Toronto, Canada. | Direktor/Vorstandsmitglied | - |
panCELLa, Inc.
 panCELLa, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Pluristyx, Inc., panCELLa, Inc. is a privately held early-stage biotechnology firm based in Toronto, CA. panCELLa was acquired by Pluristyx, Inc. on October 06, 2022. panCELLa has secured partnerships with several biotechnology partners to enhance its patent position and provide expanded access to its exclusive failsafe™ and cloaked cells™/iact cells. The Canadian company continues its internal R & D efforts to develop additional novel uses of its platform technologies in areas such as bio-production, cancer vaccination, and tolerization. The company was founded in 2015 by Armand Keating and Andras Nagy, and has created platforms that allow for the development of safe, universal, cost-effective, “ off-the-shelf ” therapeutic cell products for medicine. | Direktor/Vorstandsmitglied | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
Pancella Therapeutics, Inc.
Pancella Therapeutics, Inc. BiotechnologyHealth Technology Pancella Therapeutics, Inc. develops novel therapies for geno dermatoses. The company is headquartered in Toronto, Canada. | Health Technology |
panCELLa, Inc.
panCELLa, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Pluristyx, Inc., panCELLa, Inc. is a privately held early-stage biotechnology firm based in Toronto, CA. panCELLa was acquired by Pluristyx, Inc. on October 06, 2022. panCELLa has secured partnerships with several biotechnology partners to enhance its patent position and provide expanded access to its exclusive failsafe™ and cloaked cells™/iact cells. The Canadian company continues its internal R & D efforts to develop additional novel uses of its platform technologies in areas such as bio-production, cancer vaccination, and tolerization. The company was founded in 2015 by Armand Keating and Andras Nagy, and has created platforms that allow for the development of safe, universal, cost-effective, “ off-the-shelf ” therapeutic cell products for medicine. | Commercial Services |
